DE171496T1 - Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung. - Google Patents

Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung.

Info

Publication number
DE171496T1
DE171496T1 DE1985102665 DE85102665T DE171496T1 DE 171496 T1 DE171496 T1 DE 171496T1 DE 1985102665 DE1985102665 DE 1985102665 DE 85102665 T DE85102665 T DE 85102665T DE 171496 T1 DE171496 T1 DE 171496T1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
cells
chimeric monoclonal
gene
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1985102665
Other languages
English (en)
Inventor
Yoshikazu Lions Mansion 2-215 Showa-Ku Nagoya-Shi Aichi-Ken 468 Kurosawa
Kou-Zou Nagoya-Shi Aichi-Ken 464 Sugita
Masaru Chiba-Shi Chiba-Ken 281 Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Research Development Corp of Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15885326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE171496(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Corp of Japan filed Critical Research Development Corp of Japan
Publication of DE171496T1 publication Critical patent/DE171496T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Claims (15)

85 102 665.8 4923 AW/eg PATENTANSPRÜCHE
1. Chimärischer monoklonaler Antikörper, dadurch gekennzeichnet , daß er aus einer variablen Region, die sich von einem Tier, ausgenommen dem Menschen, ableitet und einer konstanten Region, die sich vom Menschen ableitet, besteht.
2. Chimärischer monoklonaler Antikörper nach Anspruch
1, dadurch gekennzeichnet , daß die variable Region eine Tumorzelle erkennt.
3. Chimärischer monoklonaler Antikörper nach Anspruch \
2, dadurch gekennzeichnet, daß die Tumor- * zelle ein Melanom ist.
4. Chimärischer monoklonaler Antikörper nach Anspruch 1, dadurch gekennzeichnet , daß das Tier eine Maus ist.
5. Chimärischer monoklonaler Antikörper nach Anspruch 1, dadurch gekennzeichnet , daß das Tier eine Ratte ist.
6. Biologisch funktionelles Plasmid, welches genetisch umgelagert ist, dadurch gekennzeichnet , daß es ein intaktes aktives V-Gen, welches sich von einem Tier, ausgenommen einem Menschen, ableitet, ein intaktes C-Gen, welches sich von einem Menschen ableitet, und Enhancer-Elemente enthält.
017H96
7. Biologisch funktionelles Plasmid nach Anspruch 6, dadurch gekennzeichnet , daß das V-Gen ein V-Gen ist.
8. Biologisch funktionelles Plasmid nach Anspruch 7, dadurch gekennzeichnet die Struktur V-D-J-Joining aufweist.
dadurch gekennzeichnet , daß das V1-Gen
9. Biologisch funktionelles Plasmid nach Anspruch 6, dadurch gekennzeichnet , daß das V-Gen ein V-Gen ist.
10. Biologisch funktionelles Plasmid nach Anspruch 9, dadurch gekennzeichnet , daß das V -Gen
Ij
die Struktur des V-J-Joining aufweist.
11. Verfahren zur Herstellung eines chimärischen monoklonalen Antikörpers, der aus einer variablen Region, die sich von einem Tier, ausgenommen dem Menschen, ableitet, und einer konstanten Region, die sich vom Menschen ableitet, besteht, dadurch gekennzeichnet , daß man in einen Expressionsvektor aktive Gene: V und VT, die aus den Antikörper erzeu-
H L·
genden Zellen des Tieres isoliert wurden, und Gene: C„ und CT, die aus humaner DNA isoliert wurden, einsetzt und sie dann in gezüchtete Tierzellen einführt.
12. Verfahren zur Herstellung eines chimärischen monoklonalen Antikörpers nach Anspruch 11, dadurch gekennzeichnet , daß die Antikörper erzeugenden Zellen Hybridomas, klonierte B-Zellen oder B-Zellen, die mit Epstein-Barr-Virus transformiert sind, sind.
13. Verfahren zur Herstellung eines chimärischen monoklonalen Antikörpers nach Anspruch 11, dadurch ge-
kennzeichnet, daß der Vektor pSV2-gpt, pSV2-neo oder SV40 ist.
14. Verfahren zur Herstellung eines chimärischen monoklonalen Antikörpers nach Anspruch 11, dadurch gekennzeichnet , daß die gezüchteten Tierzellen Lymphoma, Nieren-Zellen, L-Zellen, COS-Zellen oder HeLa-Zellen sind, die sich von Tieren, wie Menschen, Affen, Mäusen und ähnlichen Tieren, ableiten.
15. Transformierte Zellen, dadurch gekennzeichnet , daß sie gemäß dem Verfahren von Anspruch 11 einen chimärischen monoklonalen Antikörper erzeugen.
DE1985102665 1984-08-15 1985-03-08 Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung. Pending DE171496T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16937084A JPS6147500A (ja) 1984-08-15 1984-08-15 キメラモノクロ−ナル抗体及びその製造法

Publications (1)

Publication Number Publication Date
DE171496T1 true DE171496T1 (de) 1986-07-03

Family

ID=15885326

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1985102665 Pending DE171496T1 (de) 1984-08-15 1985-03-08 Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung.
DE19853587360 Revoked DE3587360T2 (de) 1984-08-15 1985-03-08 Verfahren zur Herstellung von chimärischen monoklonalen Antikörpern.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19853587360 Revoked DE3587360T2 (de) 1984-08-15 1985-03-08 Verfahren zur Herstellung von chimärischen monoklonalen Antikörpern.

Country Status (4)

Country Link
EP (1) EP0171496B1 (de)
JP (1) JPS6147500A (de)
CA (1) CA1339201C (de)
DE (2) DE171496T1 (de)

Families Citing this family (736)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU596585B2 (en) * 1985-03-18 1990-05-10 Genelabs Incorporated Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0536566A1 (de) * 1985-11-01 1993-04-14 Xoma Corporation Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
JPS63112995A (ja) * 1986-07-07 1988-05-18 セントコ−・インコ−ポレ−テッド 腫瘍関連抗原に特異的なキメラ齧歯類／ヒト免疫グロブリン
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
ATE143052T1 (de) * 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
JPH0698021B2 (ja) * 1986-08-01 1994-12-07 帝人株式会社 マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0623679B1 (de) * 1987-05-21 2003-06-25 Micromet AG Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
WO1988009181A2 (en) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
JP2646007B2 (ja) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0365209A3 (de) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
JP2564412B2 (ja) * 1990-03-02 1996-12-18 財団法人癌研究会 薬剤耐性癌に対するキメラ抗体およびその製造
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE4033120A1 (de) * 1990-10-18 1992-04-23 Boehringer Mannheim Gmbh Verfahren zur herstellung von chimaeren antikoerpern
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
DE69225710T3 (de) * 1991-07-25 2004-10-14 Idec Pharmaceuticals Corp., San Diego Anregung von antworten zytotoxischer t-lymphozyten
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
CA2153165C (en) * 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
KR100266554B1 (ko) * 1993-01-14 2000-09-15 사꼬 미쓰오 재조합항-hiv항체및그의제조방법
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
WO1995008336A1 (en) * 1993-09-22 1995-03-30 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
DK0730643T3 (da) 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation
EP0729976A1 (de) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Rekonstituierter humaner antikoerper gegen humane medulloblastomzellen
WO1995024501A1 (en) 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
DE69535830D1 (de) 1994-11-02 2008-10-16 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DE69740057D1 (de) 1996-07-12 2010-12-30 Bristol Myers Squibb Co Transkriptionaler Intermediärfaktor 2
DK0961831T3 (da) 1996-08-16 2009-01-12 Human Genome Sciences Inc Humant alfa-endokin
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
SI1019500T1 (sl) 1997-01-15 2007-02-28 Yeda Res & Dev Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone
ATE426018T1 (de) 1997-04-10 2009-04-15 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE69837085T3 (de) 1997-04-16 2012-01-12 Millennium Pharmaceuticals, Inc. Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
EP2060631A3 (de) 1997-04-25 2009-07-15 Aquila Biopharmaceuticals, Inc. Charakterisierung granulocytischer Ehrlichien und Verfahren zu ihrer Anwendung
WO1998049311A2 (en) 1997-04-30 1998-11-05 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
EP1015477B1 (de) 1997-05-30 2010-11-10 Human Genome Sciences, Inc. 32 Humane sekretierte Proteine
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
DE69841139D1 (de) 1997-07-14 2009-10-22 Univ Liege Mutationen im myostatingen steigern muskelmasse in säugetieren
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1015488B1 (de) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 rezeptor-ähnliches protein
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP2301947A3 (de) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Sekretierte Proteine und Verwendungen dafür
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
WO2001058949A2 (en) 2000-02-11 2001-08-16 Biogen, Inc. Heterologous polypeptide of the tnf family
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2251026A1 (de) 2000-06-08 2010-11-17 Immune Disease Institute, Inc. Verfahren und Zusammensetzungen zur Hemmung der immunoglobulinvermittelten Reperfusionsverletzung
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
BR0113512A (pt) 2000-08-25 2005-05-10 Basf Plant Science Gmbh Polinucleotìdeos de planta que codificam novas prenil proteases
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP4198990B2 (ja) 2000-10-18 2008-12-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 造血細胞のｅ−セレクチン／ｌ−セレクチンリガンドポリペプチドおよびその使用法
CA2427820A1 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CA2429722A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
CA2431861A1 (en) 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
EP1373499B1 (de) 2001-02-23 2017-09-20 Dana-Farber Cancer Institute, Inc. Hin-1, ein tumorsuppressor-gen
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
EP2278013A1 (de) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Polypeptidantigene codierende offene Leseraster aus Streptococcus Pneumoniae und Verwendungen davon
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1432431B1 (de) 2001-10-04 2017-05-10 Genetics Institute LLC Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CA2469306A1 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
DE60234713D1 (de) 2001-12-18 2010-01-21 Endocube Sas Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
AU2002367317A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
US7494655B2 (en) 2002-03-05 2009-02-24 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
JP2006511194A (ja) 2002-05-02 2006-04-06 デイビッド ラブジョイ テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
ATE345504T1 (de) 2002-05-07 2006-12-15 Pasteur Institut Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
EP2801616A1 (de) 2002-06-17 2014-11-12 Thrasos Innovation, Inc. Einzeldomänenverbindungen im Zusammenhang mit TDF und Analoga davon
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
CN101044247B (zh) 2002-08-20 2011-06-22 千年药品公司 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
MXPA05005923A (es) 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
ATE471335T1 (de) 2002-12-23 2010-07-15 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
CA2513675A1 (en) 2003-01-17 2004-08-05 The Johns Hopkins University Methods of identifying modulators of cellular glycosylation using gtrap3-18
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
ES2639301T3 (es) 2003-04-30 2017-10-26 Universität Zürich Procedimientos de tratamiento de cáncer usando una inmunotoxina
EP2374819B1 (de) 2003-05-12 2017-03-22 Helion Biotech ApS Antikörper gegen MASP-2
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP2508608A1 (de) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Verfahren zur Behandlung neurodegenerativer Erkrankungen
JP5576010B2 (ja) 2003-08-04 2014-08-20 ザ・ホスピタル・フォー・シック・チルドレン ラフォラ病遺伝子
KR20060120652A (ko) 2003-10-07 2006-11-27 밀레니엄 파머슈티컬스 인코퍼레이티드 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005047475A2 (en) 2003-11-11 2005-05-26 Regents Of The University Of Minnesota Regulation of cell membrane-mediated effects
CA2494572A1 (en) 2003-12-19 2005-06-19 Cytochroma Inc. Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof
WO2005063992A1 (ja) 2003-12-30 2005-07-14 Suntory Limited 新規血清型のストレプトコッカス ミュータンスおよびその利用
EP3476861A1 (de) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-spezifischer monoklonaler antikörper und verwendungen davon
EP1714151A4 (de) 2004-01-21 2009-06-10 Fujirebio America Inc Nachweis von mit mesothelin-/megakaryozyt-potenzierungsfaktor verwandten peptiden in peritonealflüssigkeit zur beurteilung des peritoneums und der peritonealhöhle
DK1766093T3 (da) 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
ATE498010T1 (de) 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
EP1598428A1 (de) 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
CA2571218C (en) 2004-06-17 2015-11-03 William D. Carlson Tdf-related compounds and analogs thereof
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP2287310B1 (de) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
CA2943949C (en) 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2596986A1 (en) 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
DK1871418T3 (da) 2005-04-19 2014-06-10 Seattle Genetics Inc Humaniserede anti-cd70-bindende midler og anvendelser deraf
EP1885396A2 (de) 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Rekombinante antikörper gegen cd55 und cd59 und ihre verwendungen
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP2305258A3 (de) 2005-05-31 2011-07-06 Duska Scientific Co Verhinderung von neuronalen schäden
WO2006138553A2 (en) 2005-06-17 2006-12-28 Wyeth Methods of purifying fc region containing proteins
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
PL3248613T3 (pl) 2005-07-18 2022-04-19 Seagen Inc. Koniugaty β-glukuronid-linker-lek
ES2530265T3 (es) 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
DK2497780T3 (en) 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
AU2006294481B2 (en) 2005-09-28 2012-12-20 Becton, Dickinson And Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
KR20140012160A (ko) 2005-11-01 2014-01-29 애브비 바이오테크놀로지 리미티드 바이오마커를 사용하여 강직성 척추염을 진단하기 위한 방법 및 조성물
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2007056618A1 (en) 2005-11-10 2007-05-18 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
MY151424A (en) 2006-02-17 2014-05-30 Sekiyama Atsuo Biological load indicator and method of measuring biological load
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP1854477B9 (de) 2006-03-16 2018-03-14 Dyax Corp. Peptid-Inhibitoren von Plasma Kallikrein zur Verwendung in der Behandlung von Augenerkrankungen
CA2647671A1 (en) 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666479A3 (de) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
EP2019684A4 (de) 2006-04-20 2009-08-26 Jackson H M Found Military Med Verfahren und zusammensetzungen auf der basis von shigatoxin-typ-1-protein
EP2035439A4 (de) 2006-06-05 2010-01-13 Cancer Care Ontario Abschätzung des risikos von colorectalkrebs
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8304384B2 (en) 2006-06-28 2012-11-06 Yeda Research And Development Co., Ltd Caspase-8 and inflammation, infection and wound healing
CN103316403B (zh) 2006-06-30 2017-05-24 艾伯维生物技术有限公司 自动注射装置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2046383B1 (de) 2006-07-04 2014-11-19 Genmab A/S Cd20-bindungsmoleküle zur behandlung von copd
WO2008008360A1 (en) 2006-07-13 2008-01-17 Wyeth Production of glycoproteins
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
LT2081595T (lt) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
CN101626785A (zh) 2006-11-17 2010-01-13 财团法人阪大微生物病研究会 神经延长促进剂及延长抑制剂
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008086002A2 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Slco1b3 genotype
WO2008091740A2 (en) 2007-01-22 2008-07-31 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2121745A2 (de) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteine
EP2115126B1 (de) 2007-03-02 2015-04-08 Wyeth LLC Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
CA2679954A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
EP2185688A4 (de) 2007-08-06 2010-08-25 Burnham Inst Medical Research Znf206: ein neuer regulator der selbsterneuerung und pluripotenz embryonaler stammzellen
WO2009039442A1 (en) 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
AU2008304615A1 (en) 2007-09-24 2009-04-02 Cornell University Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
EP2199391B1 (de) 2007-09-27 2015-11-11 Japan Tobacco, Inc. An latenter infektion mit herpesvirus beteiligter faktor und verwendung davon
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
CA2710984C (en) 2007-12-28 2018-05-29 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA2713055C (en) 2008-01-25 2018-03-13 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
NO2842575T3 (de) 2008-03-18 2018-02-24
US9527906B2 (en) 2008-04-18 2016-12-27 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8741287B2 (en) 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
EP2650014A2 (de) 2008-06-20 2013-10-16 Wyeth LLC Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US20100075329A1 (en) 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
KR102097887B1 (ko) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
ES2659875T3 (es) 2008-10-10 2018-03-19 Children's Medical Center Corporation Vacuna de trímero de Env VIH-1 bioquímicamente estabilizado
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
BRPI0921286B8 (pt) 2008-11-05 2022-10-25 Wyeth Llc Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs).
RU2011121042A (ru) 2008-11-26 2013-01-10 Файв Прайм Терапеутикс, Инк. Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
WO2010091182A2 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
JPWO2010110346A1 (ja) 2009-03-24 2012-10-04 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP3248618A1 (de) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
KR101721906B1 (ko) 2009-04-29 2017-03-31 애브비 바이오테크놀로지 리미티드 자동 주입 장치
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CN102481380A (zh) 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
US20120263719A1 (en) 2009-10-22 2012-10-18 Yeda Research And Development Co., Ltd. Compositions and methods for treating aspergillosis
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
TWI619521B (zh) 2009-12-15 2018-04-01 艾伯維生物技術有限責任公司 自動注射裝置、自動注射方法及防止不發射情況之方法
AU2010330907A1 (en) 2009-12-16 2012-06-14 Bosch, Phillip Methods of treating interstitial cystitis
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US9624290B2 (en) 2010-01-28 2017-04-18 Ab Biosciences, Inc. Lowered affinity antibodies and methods of making the same
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
BR112012020116B8 (pt) 2010-02-10 2023-01-10 Perseus Proteomics Inc Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer
KR101831459B1 (ko) 2010-03-03 2018-04-04 더 유니버시티 오브 브리티시 콜롬비아 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
EP4012714A1 (de) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2011125012A1 (en) 2010-04-05 2011-10-13 Wyeth Llc Biomarkers for p13k-driven cancer
BR112012026886B1 (pt) 2010-04-21 2020-11-24 Abbvie Biotechnology Ltd. dispositivo de injeção automático usável para distribuição controlada de agentes terapêuticos
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
DK2575884T3 (en) 2010-06-03 2018-09-03 Abbvie Biotechnology Ltd APPLICATIONS AND COMPOSITIONS TO TREAT HIDRADENITIS SUPPURATIVA (HS)
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
PL3246044T3 (pl) 2010-08-23 2021-08-23 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN103415615B (zh) 2010-11-24 2015-11-25 高红 扩增造血干细胞
CN103547288B (zh) 2011-01-10 2016-03-16 密执安大学评议会 干细胞因子抑制剂
EP2667918B1 (de) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatische injektionsvorrichtungen mit übersrpitzten griffflächen
PE20180776A1 (es) 2011-03-02 2018-05-07 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
JP2014513289A (ja) 2011-04-08 2014-05-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
MX345747B (es) 2011-04-21 2017-02-14 Abbvie Inc Dispositivo de inyección automático portable.
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
SI2726094T1 (sl) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Terapevtski in diagnostični cilj
WO2013014538A2 (en) 2011-07-25 2013-01-31 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2748192B2 (de) 2011-08-23 2022-04-20 Foundation Medicine, Inc. Kif5b-re-fusionsmoleküle und verwendungen davon
CA2846667A1 (en) 2011-09-06 2013-03-14 Guy L. Reed Serpinf2-binding molecules and methods of use
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
JP2014533929A (ja) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ５ｔ４およびｃｄ３に対する二重特異的結合性分子
SG11201401220SA (en) 2011-10-21 2014-07-30 Pfizer Addition of iron to improve cell culture
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AR088694A1 (es) 2011-11-17 2014-06-25 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
WO2013078455A2 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Proteomic identification of antibodies
EP2599496A1 (de) 2011-11-30 2013-06-05 Kenta Biotech AG Neuartige Targets von Acinetobacter baumannii
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
EP3485906A1 (de) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX365947B (es) 2012-03-27 2019-06-19 Genentech Inc Operaciones de cosecha mejoradas para proteinas recombinadas.
US9494597B2 (en) 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
EP2834366A4 (de) 2012-04-02 2016-04-27 Berg Llc Auf abfragezellen basierende assays und verwendungen davon
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
NZ724892A (en) 2012-05-15 2018-04-27 Seattle Genetics Inc Self-stabilizing linker conjugates
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
KR20210063443A (ko) 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 탈수초성 질환의 치료를 위한 복합 요법 및 용도
EP2912459A2 (de) 2012-10-25 2015-09-02 Life Technologies Corporation Verfahren und zusammensetzungen zur enzymvermittelten stellenspezifischen radioaktiven markierung von glykoproteinen
PL2917195T3 (pl) 2012-11-05 2018-04-30 Pfizer Inc. Analogi spliceostatyny
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CN104903351A (zh) 2012-11-07 2015-09-09 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2945652B1 (de) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Verfahren zur behandlung cholangiokarzinom
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN105143470B (zh) 2013-02-28 2020-06-09 德克萨斯大学系统董事会 用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
EP2968550B1 (de) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
CA2906784C (en) 2013-03-15 2023-02-28 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP3042667A4 (de) 2013-09-04 2017-04-05 Osaka University Dpp-4-anzielender impfstoff zur behandlung von diabetes
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN105940115B (zh) 2013-11-15 2021-07-06 巴斯德研究所 恶性疟原虫青蒿素耐药性的分子标记物
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
EP3083670A2 (de) 2013-12-17 2016-10-26 Westfälische Wilhelms-Universität Münster Vorrichtung und verfahren zur behandlung einer pruritusartigen hauterkrankung
EP3082878B1 (de) 2013-12-19 2022-10-05 Seagen Inc. Methylencarbamat-linker zur verwendung mit gezielten wirkstoffkonjugaten
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
SI3712174T1 (sl) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Protitelesa in delci proti VISTA
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
JP6164593B2 (ja) 2013-12-27 2017-07-19 国立大学法人大阪大学 Ｉｌ−１７ａを標的とするワクチン
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
WO2015103026A2 (en) 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015110935A1 (en) 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
KR102448454B1 (ko) 2014-01-29 2022-09-28 다나-파버 캔서 인스티튜트 인크. Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
EP3107557B1 (de) 2014-02-17 2021-06-09 Seagen Inc. Hydrophile antikörper-wirkstoff-konjugate
US20170065702A1 (en) 2014-02-19 2017-03-09 Cangene Corporation Methods of modulating an immune response
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
AU2015243246B2 (en) 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
EP3804745A1 (de) 2014-04-25 2021-04-14 The Brigham and Women's Hospital, Inc. Verfahren zur manipulation von alpha-fetoprotein (afp)
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
CN113846062A (zh) 2014-07-25 2021-12-28 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CA2956471A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
JP6698084B2 (ja) 2014-08-08 2020-05-27 オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
DK3189132T3 (da) 2014-09-04 2020-08-10 Stemcell Tech Inc Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
US9879086B2 (en) 2014-09-17 2018-01-30 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
BR112017009297B1 (pt) 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
EP3244924B1 (de) 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Verfahren zur steigerung der abgabe von anti-krebsmitteln an ziele
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MX2017010705A (es) 2015-02-19 2017-12-04 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
WO2016138312A2 (en) 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
MX2017012102A (es) 2015-03-20 2018-01-12 Pfizer Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
SG10201909308XA (en) 2015-04-17 2019-11-28 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
EP3285811A1 (de) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EP3337822A1 (de) 2015-08-19 2018-06-27 Rutgers, The State University of New Jersey Neuartige verfahren zur erzeugung von antikörpern
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
PT3350220T (pt) 2015-09-15 2021-08-06 Scholar Rock Inc Anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
EP3353313A2 (de) 2015-09-23 2018-08-01 Pfizer Inc Zellen und verfahren zur zellkultur
AU2016335842A1 (en) 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
JP6412906B2 (ja) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 化合物、リンカー−薬物およびリガンド−薬物複合体
CN108350077A (zh) 2015-11-03 2018-07-31 糖模拟物有限公司 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
US11814440B2 (en) 2015-11-09 2023-11-14 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3374391B1 (de) 2015-11-10 2024-04-17 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
JP2019507126A (ja) 2016-02-01 2019-03-14 ファイザー・インク ツブリシン類似体およびこれらの調製のための方法
BR112018015715A2 (pt) 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3411404B1 (de) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
JP2019509993A (ja) 2016-02-12 2019-04-11 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ（ｂ７ｈ５）抗体
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
AU2017238172A1 (en) 2016-03-21 2018-09-13 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20170274076A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017175086A1 (en) 2016-04-05 2017-10-12 Pfizer Inc. Cell culture process
CN116333140A (zh) 2016-04-08 2023-06-27 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US20190177438A1 (en) 2016-06-17 2019-06-13 Life Technologies Corporation Site-Specific Crosslinking of Antibodies
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
MX2019000327A (es) 2016-07-13 2019-04-11 Biogen Ma Inc Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes.
CN110072887A (zh) 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用
US11712480B2 (en) 2016-08-03 2023-08-01 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
EA201990470A1 (ru) 2016-08-09 2019-09-30 Сиэтл Дженетикс, Инк. Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства
EP3497237B1 (de) 2016-08-10 2022-05-04 Institut Pasteur Verfahren und reagenzien zum nachweis von piperaquinresistenter plasmodium-falciparum-malaria
US11161909B2 (en) 2016-08-15 2021-11-02 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CA3038909A1 (en) 2016-09-29 2018-04-05 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
KR20190095946A (ko) 2016-12-23 2019-08-16 브리스톨-마이어스 스큅 컴퍼니 개선된 바이오분석 및 바이오프로세싱 성질을 위한 치료용 면역글로불린 g4의 디자인
JP7360324B2 (ja) 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
AU2018211561B2 (en) 2017-01-24 2020-04-30 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
CN110582278B (zh) 2017-03-10 2023-04-18 伊姆贝拉神经疗法公司 药物组合物及其用途
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN110799529A (zh) 2017-04-22 2020-02-14 免疫治疗有限公司 改良lamp构建物
SG11201909563VA (en) 2017-04-27 2019-11-28 Seattle Genetics Inc Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
IL297073B2 (en) 2017-05-02 2023-12-01 Immunomic Therapeutics Inc LAMP constructs containing cancer antigens
AU2018261951A1 (en) 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CA3063344A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Novel cd73 antibody, preparation and uses thereof
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019055796A1 (en) 2017-09-15 2019-03-21 Bristol-Myers Squibb Company ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST
CN111148510A (zh) 2017-09-15 2020-05-12 美国安进公司 用于治疗性蛋白质的冻干药物配制品的方法
KR20200058540A (ko) 2017-10-02 2020-05-27 비스테라, 인크. Cd138에 대한 항체 분자 및 이의 용도
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111655725A (zh) 2017-10-19 2020-09-11 德比奥药物国际股份有限公司 用于治疗癌症的组合产品
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
EP3720881A1 (de) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
US20210163592A1 (en) 2017-12-11 2021-06-03 Amgen Inc Continuous manufacturing process for bispecific antibody products
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3743101A2 (de) 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Ein lösliches verkapseltes antigen enthaltende polymersome sowie verfahren zu deren herstellung und verwendung
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR20200122351A (ko) 2018-02-20 2020-10-27 시애틀 지네틱스, 인크. 소수성 아우리스타틴 f 화합물 및 그의 접합체
JP2021514193A (ja) 2018-02-21 2021-06-10 セルジーン コーポレイション Ｂｃｍａ結合抗体及びその使用
EP3530282A1 (de) 2018-02-27 2019-08-28 Diaccurate Therapeutische verfahren
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
US20210010055A1 (en) 2018-03-16 2021-01-14 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
FI3775909T3 (fi) 2018-03-26 2023-08-01 Glycanostics S R O Välineitä ja menetelmiä proteiinin glykoprofiloimiseksi
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3785732A4 (de) 2018-04-24 2022-02-23 Ampsource Biopharma Shanghai Inc. Antikörper gegen tim-3 und anwendung davon
US20210261647A1 (en) 2018-05-15 2021-08-26 Immunomic Therapeutics, Inc Lamp constructs comprising allergens
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
US20210122814A1 (en) 2018-07-11 2021-04-29 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
WO2020025792A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
US20220105176A1 (en) 2018-09-12 2022-04-07 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
US20220242957A1 (en) 2018-09-27 2022-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
BR112021005669A2 (pt) 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3870286A1 (de) 2018-10-23 2021-09-01 Scholar Rock, Inc. Rgmc-selektive inhibitoren und ihre verwendung
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
EP3891292A1 (de) 2018-12-06 2021-10-13 Pfizer Inc. Zellen mit reduzierter inhibitorproduktion und verfahren zur verwendung davon
EP3898686A1 (de) 2018-12-20 2021-10-27 Novartis AG Pharmazeutische kombinationen
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
US20220290128A1 (en) 2019-02-04 2022-09-15 National University Corporation Ehime University CAR LIBRARY AND scFv MANUFACTURING METHOD
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3924739A1 (de) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarker von progressiver multifokaler leukoenzephalopathie
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
KR20210125034A (ko) 2019-02-15 2021-10-15 우시 바이올로직스 아일랜드 리미티드 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
CN114026122A (zh) 2019-02-21 2022-02-08 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
MX2021011830A (es) 2019-03-29 2022-01-24 Atarga Llc Anticuerpo anti fgf23.
SG11202112223XA (en) 2019-05-10 2021-12-30 Takeda Pharmaceuticals Co Antibody drug conjugates
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
CN114555807A (zh) 2019-07-19 2022-05-27 费城儿童医院 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
EP4004025A1 (de) 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2-wirkstoffe und verwendungen davon
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022003268A (es) 2019-09-19 2022-06-02 Seagen Inc Liberacion selectiva de farmaco a partir de conjugados internalizados de compuestos biologicamente activos.
KR20220079606A (ko) 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
EP4045528A1 (de) 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Verbesserte lampenkonstrukte, die krebsantigene umfassen
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4048285A1 (de) 2019-10-21 2022-08-31 Novartis AG Tim-3-inhibitoren und verwendungen davon
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4061406A1 (de) 2019-11-20 2022-09-28 Bavarian Nordic A/S Rekombinante mva-viren zur intratumoralen und/oder intravenösen verabreichung zur behandlung von krebs
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
EP4081554A1 (de) 2019-12-27 2022-11-02 Affimed GmbH Verfahren zur herstellung eines bispezifischen fcyriii-x-cd30-antikörper-konstrukts
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics Inc An cd33 bindende multifunktionsmoleküle und ihre verwendungen
BR112022013733A2 (pt) 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CA3168882A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
EP4121459A1 (de) 2020-03-19 2023-01-25 Amgen Inc. Antikörper gegen mucin 17 und verwendungen davon
US20210311054A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
CN115803062A (zh) 2020-06-03 2023-03-14 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
EP4172206A1 (de) 2020-06-24 2023-05-03 Visterra, Inc. Antikörpermoleküle gegen april und verwendungen davon
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
EP4183416A1 (de) 2020-07-17 2023-05-24 Mitsubishi Tanabe Pharma Corporation Mittel zur prävention oder behandlung von muskelerkrankungen
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4204458A1 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Verfahren zum nachweis von trbc1 oder trbc2
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4208197A1 (de) 2020-09-04 2023-07-12 Rutgers, The State University of New Jersey Sars-cov-2-impfstoffe und -antikörper
EP4214223A1 (de) 2020-09-21 2023-07-26 Theravectys Verfahren und produkte mit hohem durchsatz für sars-cov-2-seroneutralisierungsassay
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced cleavage rate
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
EP4240768A2 (de) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispezifischer antigenbindender moleküle mit erhöhter selektivität
AR124019A1 (es) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen a cd3
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
EP4255466A1 (de) 2020-12-04 2023-10-11 Visterra, Inc. Verfahren zur verwendung von interleukin-2-wirkstoffen
EP4277664A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antikörper-pyrrolobenzodiazepinderivat-konjugat
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
US20220226442A1 (en) 2021-01-20 2022-07-21 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
CA3206244A1 (en) 2021-02-03 2022-08-11 Kung-Pern WANG Immunostimulatory compounds and conjugates
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4314078A1 (de) 2021-04-02 2024-02-07 Amgen Inc. Mageb2-bindende konstrukte
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CN117440798A (zh) 2021-04-12 2024-01-23 Acm 生物实验室私人有限公司 包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
KR20240015670A (ko) 2021-05-28 2024-02-05 씨젠 인크. 안트라사이클린 항체 접합체
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Transgenic T cell receptors attached to antibody binding sites
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
AU2022346688A1 (en) 2021-09-14 2024-04-04 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023102463A1 (en) 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
TW202400137A (zh) 2022-03-17 2024-01-01 美商思進公司 喜樹鹼偶聯物
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023223092A1 (en) 2022-05-18 2023-11-23 Institut Pasteur Identification of a human circovirus
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations

Also Published As

Publication number Publication date
EP0171496A3 (en) 1987-11-25
DE3587360D1 (de) 1993-07-01
EP0171496A2 (de) 1986-02-19
EP0171496B1 (de) 1993-05-26
JPS6147500A (ja) 1986-03-07
CA1339201C (en) 1997-08-05
JPH0373280B2 (de) 1991-11-21
DE3587360T2 (de) 1993-10-14

Similar Documents

Publication Publication Date Title
DE171496T1 (de) Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung.
DE3301249C2 (de)
DE3051086C2 (de)
KR930700662A (ko) 인간화된 단클론성 항체 및 혼성 단클론성 항체
Liesegang et al. Isolation of myeloma variants with predefined variant surface immunoglobulin by cell sorting.
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE69033937T2 (de) Verfahren zur Herstellung von genetischen Vektoren zur Expression vom Nerven-Wachstumsfaktor in eukaryotischen Zellen
DE69635639T2 (de) Interleukin-12-beta-Rezeptoren mit niedriger Bindungsaffinität
DE3650790T2 (de) Menschlisches Interferon-Beta 2A zur Verwendung als Arzneimittel
DE3222072A1 (de) Humane t-zell-linien und verfahren zu ihrer herstellung
DE69124518D1 (de) Herstellung monoklonaler Antikörper gegen menschliches Vbeta T-Zellrezeptorelement unter Verwendung rekombinanter DNA-Vektoren
DE69735872T2 (de) Menschliches adhäsionsmolekül occludin
DE69929876T2 (de) Für hm1.24 antigen kodierendes gen und dessen promotor
JPS60500358A (ja) マウスの細胞内で組み換えｄｎａによって生産されたヒト成長ホルモン
DE2819110C2 (de) Verfahren zur Synthese von biologischen Peptidwirkstoffen
EP0133551A2 (de) Monoklonaler Antikörper, der eine Struktur erkennt die dem Human-Interleukin-2 (TCGF) und der leichten Kette "lambda" von Humanimmunglobulin gemeinsam ist, und Hybridoma-Zell-Linien, die diese monoklonalen Antikörper produzieren
Bucher Generation of a virus specific immunoglobulin transgenic mouse by homologous recombination
DE60130488T2 (de) Verfahren zur identifizierung von ein physiologisch aktives polypeptid kodierender dna in einem nagetier
Hepper Sibling recognition in the rat: Change in stimulus value or individual preference?
Desvaux et al. Antibody diversity in trouts obtained by gynogenesis or self-fertilization. Comparative analysis of the heavy chain spectrotypes
DE69837380T2 (de) Biologisches material zur behandlung eines säugetieres durch transfer eines für einen antikörper kodierendes gen und eine pharmazeutische zusammensetzung die diese enthält
DE3512559A1 (de) Hypoxanthin-guanin-phosphoribosyltransferase-negative mutante einer histiozytischen permanenten humanen zellinie
EP0205032A2 (de) Thymidin-Kinase(EC 2.7.1.21)-Mangelmutanten einer humanen monocytischen Zellinie
DE3138230A1 (de) Verfahren zur gewinnung von makrophagen- aktivierungsfaktor (maf)
CHUONG NEURAL CELL ADHESION MOLECULES IN THE DEVELOPMENT OF THE BRAIN (MONOCLONAL ANTIBODY, STAGGERER MUTANT, AGGREGATION)